CIPERF )Ciprofloxacin 0.2%( is a second-generation fluoroquinolone, a broad-spectrum antimicrobial agent for intravenous administration.

Each vial of CIPERF contains Ciprofloxacin 200 mg / 100 ml.

Adults:

Lower respiratory tract Infections due to Gram-negative bacteria:

Exacerbations of chronic obstructive pulmonary disease.

Broncho-pulmonary infections in cystic fibrosis or in bronchiectasis.

Pneumonia.

Chronic suppurative otitis media.

Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria.

Urinary tract infections.

Genital tract infections:

Epididymo-Orchitis including cases due to susceptible Neisseria gonorrhoeae.

Pelvic inflammatory disease including cases due to susceptible Neisseria gonorrhoeae.

Infections of the gastro-intestinal tract (e.g. travellers’ diarrhea).

Intra-abdominal infections.

Infections of the skin and soft tissue caused by Gram-negative bacteria.

Malignant external otitis.

Infections of bones and joints.

Inhalation anthrax (post-exposure prophylaxis and curative treatment), (Drug administration should begin as soon as possible after suspected or confirmed exposure).

Neutropenic patients with fever that is suspected to be due bacterial infection.

Children and adolescents:

Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa.

Complicated urinary tract infections and pyelonephritis

Inhalation anthrax (post-exposure prophylaxis and curative treatment), (Drug administration should begin as soon as possible after suspected or confirmed exposure).

Treating other severe infections when this is considered to be necessary.

Pregnancy& breast-feeding

Pregnancy: As a precaution measure, it is preferable to avoid the use of ciprofloxacin during pregnancy. (Pregnancy category: C).

Breast-feeding: Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.

Adults:

Lower respiratory tract Infections, acute exacerbation of chronic sinusitis, chronic suppurative otitis media and infections of the skin and soft tissue:

400 mg twice daily to 400 mg three times a day for 7 to 14 days.

Malignant external otitis:

400 mg three times a day for 28 days up to 3 months.

Complicated and uncomplicated pyelonephritis:

400 mg twice daily to 400 mg three times a day for 7 to 21 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses).

Prostatitis:

400 mg twice daily to 400 mg three times a day for 2 to 4 weeks (acute).

Epididymo-Orchitis and Pelvic inflammatory disease:

 twice daily to 400 mg three times a day for at least 14 days.

Infections of the gastro-intestinal tract and Intra-abdominal infections:

Diarrhea caused by bacterial pathogens including Shigella spp. (other than Shigella dysenteriae type 1 and empirical treatment of severe travellers’ diarrhea):

400 mg twice daily for 1 day.

Diarrhea caused by Shigella dysenteriae type 1:

400 mg twice daily for 5 days.

Diarrhea caused by Vibrio cholera:

400 mg twice daily for 3 days.

Typhoid fever:

400 mg twice daily for 7 days.

Intra-abdominal infections due to Gram-negative bacteria:

400 mg twice daily to 400 mg three times a day for 5 to 14 days.

Bone and joint infections:

400 mg twice daily to 400 mg three times a day for 3 months Maximum.

Neutropenic patients with fever that is suspected to be due bacterial infection:

400 mg twice daily to 400 mg three times a day.

Therapy should be continued over the entire period of neutropenia. (Ciprofloxacin should be co-administrated with appropriate antibacterial agent(s) in accordance to official guidance).

Inhalation anthrax post-exposure prophylaxis and curative treatment for persons requiring parenteral treatment:

400 mg twice daily for 60 days from the confirmation of Bacillus anthracis exposure.

Pediatric population:

Cystic fibrosis:

10 mg / kg body weight three times a day with a maximum of 400 mg per dose for 10 to 14 days.

Complicated urinary tract infections and pyelonephritis:

6 mg / kg body weight three times a day to 10 mg / kg body weight three times a day with a maximum of 400 mg per dose for 10 to 21 days.

Inhalation anthrax post-exposure prophylaxis and curative treatment for persons requiring parenteral treatment:

10 mg / kg body weight twice daily to 15 mg / kg body weight twice daily with a maximum of 400 mg per dose for 60 days from the confirmation of Bacillus anthracis exposure.

Other severe infections:

10 mg / kg body weight three times a day with a maximum of 400 mg per dose, the duration of treatment is according to the type of infections.

Method of administration:

In adult patients, infusion time is 60 minutes for 400 mg Ciprofloxacin solution for infusion and 30 minutes for 200 mg Ciprofloxacin solution for infusion. For children, the infusion duration is 60 minutes.

Slow infusion into a large vein will minimize patient discomfort and reduce the risk of venous irritation.